Showing results (251-260 of 300) with videos related to
Sort By:
Pageof 30
The Oncologist|April 21, 2022
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:
Safety, Efficacy, and BiomarkersYakun Wang, Tianshu Liu, Gongyan Chen, et al.Oncology Letters|March 7, 2024
Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trialXi Guo, Wenhui Lou, Yaolin Xu, et al.Annals of Surgery|November 20, 2020
Preoperative Hepatic and Regional Arterial Chemotherapy in Patients Who Underwent Curative Colorectal Cancer Resection: A Prospective, Multi-center, Randomized Controlled TrialDexiang Zhu, Jianguo Xia, Yan Gu, et al.Cancer Immunology, Immunotherapy : CII|May 10, 2024
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket studyShengxiang Ren, Anwen Xiong, Jia Yu, et al.The Lancet. Oncology|May 1, 2019
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trialZefei Jiang, Wei Li, Xichun Hu, et al.Nature Communications|September 29, 2022
Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategiesYan Li, Chen Xu, Bing Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2023
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic CancerShukui Qin, Jin Li, Yuxian Bai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2026
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I TrialTianshu Liu, Suxia Luo, Xianglin Yuan, et al.International Journal of Cancer|September 19, 2022
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysisTianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 11, 2024
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumorsJian Li, Ye Xu, Aimin Zang, et al.Pageof 30